交銀國際(03329.HK)擬認購子基金A類股份 涉資3236萬美元
格隆匯12月27日丨交銀國際(03329.HK)發佈公告,2019年12月27日,附屬公司(作為代表公司行事代理人)簽訂申請表,據此,附屬公司申請按私人配售備忘錄條款與條件認購子基金A類股份,總金額為3236萬美元。於同一日,附屬公司(作為代表公司行事代理人)與基金公司(代表子基金)、管理人及投資顧問訂立附函,據此,附屬公司有權作為子基金投資者享有若干經濟利益。
該子基金名稱為“New China Innovation Fund 27 Segregated Portfolio”,子基金目標規模為1億美元。配售參與股份乃以最低總認購金額7000萬美元為先決條件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.